1 min read
Chief Medical Officer Summit -CMO 360°
Meet the Veristat team at Booth #3, April 17th and 18th in Boston
The Science-First CRO™ and Consultancy Ready to...
2 min read
May 2021
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval. Below are the relevant links to updates provided for both COVID-19 related and non-COVID-19 related programs in May 2021.
New FDA Guidance Documents:
Qualified Infectious Disease Product Designation – Questions and Answers – Guidance for Industry (published 11May2021)
S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals (published 11May2021)
Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Annex (published 11May2021)
Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Guidance for Industry (published 11May2021)
S5(R3) Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals (published 11May2021)
Q3D(R2) – Guideline for Elemental Impurities-Investigators (published 11May2021)
E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials (published 11May2021)
COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention (published 17May2021)
Manufacturing, Supply Chain, and Drug and Biological Product Inspections During COVID-19 Public Health Emergency Questions and Answers (published 17May2021)
Bispecific Antibody Development Programs Guidance for Industry (published 20May2021)
Emergency Use Authorization for Vaccines to Prevent COVID-19 (published 25May2021)
New Draft Guidance Documents:
Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases Guidance for Sponsor-Investigators (published 11May2021)
Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) (Revision 1) (published 17May2021)
Chemotherapy-Induced Nausea and Vomiting: Developing Drugs for Prevention Guidance for Industry (published 19May2021)
Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products (published 20May2021)
ICH Q12: Implementation Considerations for FDA-Regulated Products (published 20May2021)
ICH announces sign-off of residual solvent guideline (published 03May2021)
BsUFA talks continue on technology, regulatory science and reviews (published 04May2021)
Panelists: Sluggish pace of DSCSA testing is worrisome (published 04May2021)
FDA welcomes alternative approaches to generic drug development (published 05May2021)
FDA tallies pandemic inspection toll, issues new 'resiliency roadmap' (published 05May2021)
Global regulators issue call for clinical trial data transparency (published 07May2021)
Shuren updates on inspections, ISO 13485 and MDUFA V (published 10May2021)
FDA issues ICH Q12 guidance and others on clinical trials, safety testing and biowaivers (published 11May2021)
FDA finalizes QIDP Q&A guidance (published 11May2021)
Capacity adjustments, DMFs under discussion for GDUFA III (published 12May2021)
FDA calls for input on peptide evaluation (published 13May2021)
To speed drug development, ICH proposes reducing rat carcinogenicity testing (published 14May2021)
FDA: Flexibility okay for gaps in gene therapy trials (published 18May2021)
FDA clarifies potential actions when onsite inspections are infeasible (published 18May2021)
FDA clarifies deferral policy on pediatric studies for new cancer drugs (published 24May2021)
FDA may decline new COVID vaccine EUA requests (published 25May2021)
BsUFA III negotiations turn to supplements, technology proposals (Published 26May2021)
-
Review the recording from our webinar: How to Better Plan Your Virtual Clinical Trial
-
Learn how Veristat experts can help you better plan your decentralized clinical trials: Adopting Decentralized Clinical Trials
- Download our COVID-19 Guide on Strategies For Success During the COVID-19 Era
- Read our infographic to Understand FDA Expedited Pathways for Accelerating Time-to-Market for Products Treating Serious Conditions or Unmet Medical Needs
- Download the Infographic explaining the Types of FDA Meetings with CDER and CBER